Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(6). https://doi.org/10.4081/hmr.v2i6.771